Terms: = Germ cell tumor AND STIL, SIL, 6491, ENSG00000123473, Q15468 AND Prognosis
11 results:
1. [Successful Postoperative Recurrence Treatment of Malignant Melanoma of the Esophagus by Anti-PD-1 and Anti-CTLA-4 Combined Therapy-A Case Report].
Minagawa Y; Tanaka Y; Funatsuya T; Takahashi M
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1160-1162. PubMed ID: 36281619
[TBL] [Abstract] [Full Text] [Related]
2. Research of differential expression of sil1RAP in low-grade gliomas between children and adults.
He J; Li X; Zhu W; Yu Y; Gong J
Brain Tumor Pathol; 2018 Jan; 35(1):19-28. PubMed ID: 29238884
[TBL] [Abstract] [Full Text] [Related]
3. Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma.
Egler RA; Burlingame SM; Nuchtern JG; Russell HV
Clin Cancer Res; 2008 Nov; 14(21):7028-34. PubMed ID: 18980999
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of serum levels of cytokines and intercellular adhesion molecule-1 (ICAM-1) in astrocytic tumours.
Nano R; Capelli E; Argentina F; Facoetti A; Gerzeli G
Cell Mol Biol (Noisy-le-grand); 2003 Jun; 49(4):525-8. PubMed ID: 12899444
[TBL] [Abstract] [Full Text] [Related]
5. Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma.
Raffaghello L; Pagnan G; Pastorino F; Cosimo E; Brignole C; Marimpietri D; Bogenmann E; Ponzoni M; Montaldo PG
Cancer Lett; 2003 Jul; 197(1-2):151-5. PubMed ID: 12880975
[TBL] [Abstract] [Full Text] [Related]
6. In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma.
Raffaghello L; Pagnan G; Pastorino F; Cosimo E; Brignole C; Marimpietri D; Montaldo PG; Gambini C; Allen TM; Bogenmann E; Ponzoni M
Int J Cancer; 2003 May; 104(5):559-67. PubMed ID: 12594810
[TBL] [Abstract] [Full Text] [Related]
7. Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma.
Vuoristo MS; Laine S; Huhtala H; Parvinen LM; Hahka-Kemppinen M; Korpela M; Kumpulainen E; Kellokumpu-Lehtinen P
Eur J Cancer; 2001 Sep; 37(13):1629-34. PubMed ID: 11527688
[TBL] [Abstract] [Full Text] [Related]
8. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma.
Boyano MD; Garcia-Vázquez MD; López-Michelena T; Gardeazabal J; Bilbao J; Cañavate ML; Galdeano AG; Izu R; Díaz-Ramón L; Raton JA; Díaz-Pérez JL
Br J Cancer; 2000 Oct; 83(7):847-52. PubMed ID: 10970683
[TBL] [Abstract] [Full Text] [Related]
9. Clinical implication of serum sil-2R levels in ovarian cancer.
Wang S; Cai G; Lu Y
J Tongji Med Univ; 1998; 18(2):126-8. PubMed ID: 10806842
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
Gebauer G; Rieger M; Jäger W; Lang N
Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
[TBL] [Abstract] [Full Text] [Related]
11. Soluble interleukin-2 receptor levels in patients with malignant melanoma and renal cell cancer.
Ostenstad B
Acta Oncol; 1992; 31(4):413-5. PubMed ID: 1632975
[TBL] [Abstract] [Full Text] [Related]
